Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to show that ViscoGel® is safe when administrated alone and as an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune response.
Epistemonikos ID: 59094f6b91bb28c665e70b224fe3eb85c87e8adf
First added on: May 10, 2024